Search Results - "Bartelink, I"

Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen by Bognàr, T. (Tim), Kingma, J. S. (Jurjen), Smeijsters, E. H. (Erin), van der Elst, K. C. M. (Kim), de Kanter, C. T. M. (Klaartje), Lindemans, C. A. (Caroline), Egberts, A. C. G. (Toine), Bartelink, I. H. (Imke), Lalmohamed, A. (Arief)

“…Busulfan exposure has previously been linked to clinical outcomes, hence the need for therapeutic drug monitoring (TDM). Study objective was to evaluate the…”
Get full text

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients by Bartelink, I H, van de Stadt, E A, Leeuwerik, A F, Thijssen, V L J L, Hupsel, J R I, van den Nieuwendijk, J F, Bahce, I, Yaqub, M, Hendrikse, N H

“…Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR…”
Get full text

Busulfan Exposure Target Attainment in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: A Single Day Versus a Multiple Day Therapeutic Drug Monitoring Regimen by Bognàr, T., Bartelink, I.H., van der Elst, K.C.M., Kingma, J.S., Smeijsters, E.H., Lindemans, C.A., Egberts, A.C.G., Kuball, J.H.E., de Witte, M.A., Schultink, A.H.M. de Vries, Lalmohamed, A.

“…•Performing busulfan TDM on both day 1 and day 2, rather than only on day 1, improves busulfan target exposure attainment in adults undergoing HCT.•This trend…”
Get full text

The narrow road to expanded access by Post, H.C., Schutte, T., Voortman, J., Bartelink, I.H., van Laarhoven, H.W.M., Crul, M.

Get full text

New Paradigm for Translational Modeling to Predict Long‐term Tuberculosis Treatment Response by Bartelink, IH, Zhang, N, Keizer, RJ, Strydom, N, Converse, PJ, Dooley, KE, Nuermberger, EL, Savic, RM

“…Disappointing results of recent tuberculosis chemotherapy trials suggest that knowledge gained from preclinical investigations was not utilized to maximal…”
Get full text

Fludarabine and Exposure-Targeted Busulfan Compares Favorably with Busulfan/Cyclophosphamide-Based Regimens in Pediatric Hematopoietic Cell Transplantation: Maintaining Efficacy with Less Toxicity by Bartelink, I.H, van Reij, E.M.L, Gerhardt, C.E, van Maarseveen, E.M, de Wildt, A, Versluys, B, Lindemans, C.A, Bierings, M.B, Boelens, Jaap Jan

“…Abstract Busulfan (Bu) is used as a myeloablative agent in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). In line with…”
Get full text

Fludarabine + Exposure-Targeted Busulfan in Children with Malignant and Non-Malignant Diseases: An Effective and Low Toxic Regimen by Boelens, J.J, Bartelink, I, Lindemans, C.A, Bierings, M

Get full text

Estimation of glomerular filtration rate for drug dosing in patients with very high or low body mass index by Donker, Erik M., Bet, Pierre, Nurmohamed, Azam, Serné, Erik, Burchell, George Louis, Friedman, Allon N., Bouquegneau, Antoine, Lemoine, Sandrine, Ebert, Natalie, Cirillo, Massimo, Agtmael, Michiel A., Bartelink, Imke H.

“…An accurate estimated glomerular filtration rate (eGFR) is essential in drug dosing. This study demonstrates the limitations of indexed (ml/min/1.73 m2) and…”
Get full text

Impact of Adherence and Anthropometric Characteristics on Nevirapine Pharmacokinetics and Exposure Among HIV-Infected Kenyan Children by Vreeman, Rachel C, Nyandiko, Winstone M, Liechty, Edward A, Busakhala, Naftali, Bartelink, Imke H, Savic, Rada M, Scanlon, Michael L, Ayaya, Samual O, Blaschke, Terry F

“…BACKGROUND:There are insufficient data on pediatric antiretroviral therapy (ART) pharmacokinetics (PK), particularly for children in low- and middle-income…”
Get full text

156: Once-daily intravenous busulfan versus oral busulfan in children prior to stem cell transplantation by Boelens, J.J, Bartelink, I, Bredius, R, Zwaveling, J, Bierings, M, Rademaker, K, Ververs, T, van Kesteren, C

Get full text

298 Cd3+Cd4+-Lymphocytes as Biomarker Predicting the Outcome of Pediatric Haematopoietic Stem Cell Transplantation Recipients by Bartelink, I, Belitser, S V, Knibbe, C A J, Danhof, M, De Pagter, P J, Egberts, A C G, Boelens, J J

“…Introduction: Haematopoietic stem cell transplantation (HSCT) may be complicated by severe infectious complications, graft-versus-host disease (GvHD) and…”
Get full text

Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis by Bartelink, Imke H, PhD, Lalmohamed, Arief, PharmD, van Reij, Elisabeth M L, PharmD, Dvorak, Christopher C, MD, Savic, Rada M, PhD, Zwaveling, Juliette, PharmD, Bredius, Robbert G M, MD, Egberts, Antoine C G, Prof, Bierings, Marc, MD, Kletzel, Morris, MD, Shaw, Peter J, MD, Nath, Christa E, PhD, Hempel, George, MD, Ansari, Marc, MD, Krajinovic, Maja, Prof, Théorêt, Yves, PhD, Duval, Michel, Prof, Keizer, Ron J, PharmD, Bittencourt, Henrique, MD, Hassan, Moustapha, MD, Güngör, Tayfun, MD, Wynn, Robert F, MD, Veys, Paul, MD, Cuvelier, Geoff D E, MD, Marktel, Sarah, MD, Chiesa, Robert, MD, Cowan, Morton J, MD, Slatter, Mary A, MD, Stricherz, Melisa K, PharmD, Jennissen, Cathryn, PharmD, Long-Boyle, Janel R, PharmD, Boelens, Jaap Jan, Dr

“…Summary Background Intravenous busulfan combined with therapeutic drug monitoring to guide dosing improves outcomes after allogeneic haemopoietic cell…”
Get full text

Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations by BARTELINK, Imke H, RADEMAKER, Carin M. A, SCHOBBEN, Alfred F. A. M, VAN DEN ANKER, John N

“…The approach to paediatric drug dosing needs to be based on the physiological characteristics of the child and the pharmacokinetic parameters of the drug. This…”
Get full text

Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation by Bognàr, Tim, Bartelink, Imke H., Egberts, Toine C.G., Rademaker, Carin M.A., Versluys, A. Birgitta, Slatter, Mary A., Kletzel, Morris, Nath, Christa E., Cuvelier, Geoffrey D.E, Savic, Rada M., Dvorak, Christopher, Long-Boyle, Janel R., Cowan, Morton J., Bittencourt, Henrique, Bredius, Robbert G.M., Güngör, Tayfun, Shaw, Peter J., Ansari, Marc, Hassan, Moustapha, Krajinovic, Maja, Hempel, Georg, Marktel, Sarah, Chiesa, Robert, Théoret, Yves, Lund, Troy, Orchard, Paul J., Wynn, Robert F., Boelens, Jaap Jan, Lalmohamed, Arief

“…Intravenous busulfan is widely used as part of myeloablative conditioning regimens in children and young adults undergoing allogeneic hematopoietic cell…”
Get full text

Genetic Determinants of Busulfan Clearance and Outcomes in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation- Result of a Multicentric Prospective Study on Behalf of the Pediatric Disease Working Party of the European Blood and Marrow Transplantation Group by Ansari, Marc, Rezgui, M A, Uppugunduri, Chakradhara Rao S, Théoret, Yves, Chalandon, Yves, Dupuis, LL, Schechter, Tal, Bartelink, IH, Boelens, Jaap Jan, Dalle, Jean-Hugues, Azarnoush, Saba, Sedlacek, Petr, Lewis, Victor A., Mezziani, S, Vachon, M-F, Duval, Michel, Champagne, Martin A., Peters, Christina, Bittencourt, Henrique, Krajinovic, Maja

“…▪ Busulfan (BU) dose adjustment following therapeutic drug concentration monitoring improves outcomes of hematopoietic stem cell transplantation (HSCT)…”
Get full text

156: Once-daily intravenous busulfan versus oral busulfan in children prior to stem cell transplantation: Study of pharmacokinetics and clinical outcomes by Boelens, J.J., Bartelink, I., Bredius, R., Zwaveling, J., Bierings, M., Rademaker, K., Ververs, T., van Kesteren, C.

Get full text

Busulfan Exposure Predicts Event Free Survival and Toxicity after Hematopoietic Cell Transplantation in Children And Young Adults: A Multicenter Retrospective Cohort Analysis by Bartelink, IH, Lalmohamed, A, van Reij, EM, Dvorak, CC, Savic, RM, Zwaveling, J, Bredius, RG, Egberts, AC, Bierings, M, Kletzel, M, Shaw, PJ, Nath, CE, Hempel, G, Ansari, M, Krajinovic, M, Theoret, Y, Duval, M, Keizer, RJ, Bittencourt, H, Hassan, M, Gungor, T, Wynn, RF, Veys, P, Cuvelier, GD, Marktel, S, Chiesa, R, Cowan, MJ, Slatter, MA, Stricherz, MK, Jennissen, C, Long-Boyle, JR, Boelens, JJ

Get full text